Pediatrix Medical Group (NYSE: MD) keeps 2026 EBITDA view as payor mix holds

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. provided an update on second quarter 2026 business trends, noting that its payor mix remained stable and unchanged relative to recent historical trends and internal expectations, despite reports of adverse utilization and reimbursement shifts elsewhere in the healthcare sector.

The company stated it has not experienced unfavorable payor mix shifts or material changes in other net revenue-related trends. Pediatrix reaffirmed its full year 2026 outlook for Adjusted EBITDA in a range of $280 million to $300 million, supported by a reconciliation from net income. Pediatrix plans to discuss results for the quarter ended June 30, 2026 on an investor conference call and webcast on August 4, 2026 at 9:00 a.m. ET.

Positive

• Reaffirmed 2026 Adjusted EBITDA guidance of $280–$300 million and reported a stable payor mix and net revenue trends despite adverse shifts reported by other healthcare providers.

Negative

• None.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Adjusted EBITDA guidance low end: $280 million Adjusted EBITDA guidance high end: $300 million Net income (low end, in thousands): 152,100 +4 more

7 metrics

Adjusted EBITDA guidance low end $280 million Full year 2026 anticipated Adjusted EBITDA range

Adjusted EBITDA guidance high end $300 million Full year 2026 anticipated Adjusted EBITDA range

Net income (low end, in thousands) 152,100 Reconciliation of net income to Adjusted EBITDA, year ended December 31, 2026

Net income (high end, in thousands) 166,700 Reconciliation of net income to Adjusted EBITDA, year ended December 31, 2026

Interest expense (in thousands) 33,500 Reconciliation of net income to Adjusted EBITDA, year ended December 31, 2026

Income tax provision (low end, in thousands) 56,300 Reconciliation of net income to Adjusted EBITDA, year ended December 31, 2026

Income tax provision (high end, in thousands) 61,700 Reconciliation of net income to Adjusted EBITDA, year ended December 31, 2026

Key Terms

Adjusted EBITDA, payor mix, Regulation FD Disclosure, Non-GAAP Measures, +1 more

5 terms

Adjusted EBITDA financial

"Pediatrix reaffirms its previously reported full year 2026 outlook for Adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

payor mix financial

"the Company confirms that its payor mix for the second quarter remained stable"

Payor mix is the breakdown of a healthcare provider’s customers by how their care is paid for—private insurance, government programs (like Medicare or Medicaid), self-pay, or other sources. It matters to investors because different payors pay different amounts and on different schedules, so a shift toward lower-paying or slower-paying sources can squeeze revenue and cash flow much like a store seeing more customers using discounted coupons instead of full-price cash.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. Exhibit 99.1 is incorporated by reference"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Non-GAAP Measures financial

"Non-GAAP Measures A reconciliation of projected full year 2026 Adjusted EBITDA"

Financial results that companies present using formulas or adjustments different from standard accounting rules (GAAP) to highlight what management considers the business’s ongoing performance. Investors care because these figures can make trends or profitability look clearer—like showing a car’s fuel efficiency after removing unusual trips—but they can also hide one‑time costs or aggressive assumptions, so comparing them with GAAP numbers helps judge reliability.

forward-looking statements regulatory

"Certain statements and information in this press release may be deemed to contain forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Earnings Snapshot

Adjusted EBITDA guidance range: $280 million to $300 million · Guidance included

Year ending December 31, 2026

Adjusted EBITDA guidance range $280 million to $300 million

Guidance

The company reaffirmed its previously reported full year 2026 Adjusted EBITDA outlook, anticipating a range of $280 million to $300 million.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 07/15/2026 - 07:00 AM Accepted by SEC EDGAR 07/15/2026 - 07:00 AM Learn about SEC filing dates

FAQ

What 2026 Adjusted EBITDA outlook did Pediatrix Medical Group (MD) reaffirm?

Pediatrix reaffirmed full year 2026 Adjusted EBITDA guidance of $280 million to $300 million. This outlook is supported by a reconciliation from projected net income and reflects management’s current expectations for operating performance over the year.

How did Pediatrix Medical Group (MD) describe its Q2 2026 payor mix?

Pediatrix reported that its second quarter 2026 payor mix remained stable and unchanged versus recent historical trends. The company also stated it has not seen the unfavorable payor mix shifts that some other healthcare sector participants have reported.

Did Pediatrix Medical Group (MD) see changes in net revenue trends in Q2 2026?

Pediatrix stated it has not seen material changes in other net revenue-related trends compared to recent historical periods. This suggests overall revenue dynamics, beyond payor mix, have been tracking in line with the company’s internal expectations.

When will Pediatrix Medical Group (MD) release detailed Q2 2026 results?

Pediatrix plans to issue a detailed press release on August 4, 2026 before markets open. That same day at 9:00 a.m. ET, management will host an investor conference call and webcast to discuss results for the quarter ended June 30, 2026.

What items are included in Pediatrix Medical Group’s (MD) 2026 Adjusted EBITDA reconciliation?

The 2026 Adjusted EBITDA reconciliation starts with net income and adds interest expense, income tax provision, depreciation and amortization, and transformational and restructuring related expenses. This bridge yields Adjusted EBITDA between $280,000 and $300,000 (in thousands) for the year.

What key risks does Pediatrix Medical Group (MD) highlight related to its outlook?

Pediatrix notes that forward-looking statements involve risks and uncertainties, citing factors such as economic conditions, healthcare reform, payor mix shifts, Medicaid funding, surprise billing legislation, debt arrangements, and the impact of its transformation and practice portfolio management initiatives.

0000893949false00008939492026-07-152026-07-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2026

Pediatrix Medical Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

Florida			001-12111	26-3667538
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1301 Concord Terrace
Sunrise, Florida				33323
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 954 384-0175

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $.01 per share		MD		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 15, 2026, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release providing an update for the Company’s recently completed second quarter (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

Exhibit 99.1 is incorporated by reference into this Item 7.01.

The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K and the Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

Exhibit Index

99.1— Press Release of Pediatrix Medical Group, Inc. dated July 15, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Pediatrix Medical Group, Inc.
Date:	July 15, 2026	By:	/s/ Kasandra H. Rossi
			Kasandra H. Rossi Chief Financial Officer

FOR MORE INFORMATION:

Kasandra H. Rossi

Executive Vice President, Chief Financial Officer & Treasurer

954-692-7163

kasandra.rossi@pediatrix.com

FOR IMMEDIATE RELEASE

Pediatrix Medical Group Provides Second Quarter Update

FORT LAUDERDALE, Fla., July 15, 2026 - Pediatrix Medical Group, Inc. (NYSE: MD) (“Pediatrix” or “the Company”), a leading provider of physician services, today provided an update on its second quarter 2026 business trends.

In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the Company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the Company’s internal expectations. To date, Pediatrix has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector. In addition, Pediatrix has not seen material changes in other net revenue-related trends compared to recent historical periods.

Pediatrix reaffirms its previously reported full year 2026 outlook for Adjusted EBITDA, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million.

Earnings Conference Call

Pediatrix will host an investor conference call and webcast on Tuesday, August 4, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2026. A detailed press release will be issued the morning of August 4, 2026 before the securities markets open.

The investor conference call will be webcast and can be accessed at Pediatrix’s website, www.pediatrix.com/investors.

Non-GAAP Measures

A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is provided in the financial table of this press release.

ABOUT PEDIATRIX MEDICAL GROUP

Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, its full year 2026 guidance, future impacts of legal, regulatory, political and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: completion of the Company’s second quarter closing process, the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the effects of economic conditions on the Company’s business; the effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors and any shifts in the Company’s payor mix; the impact

2

of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements and the Company’s ability to replace, refinance or extend its current debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal-fetal service lines.

###

3

Pediatrix Medical Group, Inc.

Reconciliation of Net Income to Forward-Looking Adjusted EBITDA

(in thousands)

(Unaudited)

		Year Ended December 31, 2026
Net income		$	152,100			$	166,700
Interest expense			33,500				33,500
Income tax provision			56,300				61,700
Depreciation and amortization expense			24,800				24,800
Transformational and restructuring related expenses			13,300				13,300
Adjusted EBITDA		$	280,000			$	300,000

4

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 47.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB